124 related articles for article (PubMed ID: 10692560)
1. alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil.
Cao S; Baccanari DP; Rustum YM; Davis ST; Tansik RL; Porter DJ; Spector T
Biochem Pharmacol; 2000 Apr; 59(8):953-60. PubMed ID: 10692560
[TBL] [Abstract][Full Text] [Related]
2. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Cao S; Rustum YM; Spector T
Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ
Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil.
Zhang RW; Soong SJ; Liu TP; Barnes S; Diasio SB
Drug Metab Dispos; 1992; 20(1):113-9. PubMed ID: 1346985
[TBL] [Abstract][Full Text] [Related]
5. Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells.
Diasio RB; Schuetz JD; Wallace HJ; Sommadossi JP
Cancer Res; 1985 Oct; 45(10):4900-3. PubMed ID: 3928143
[TBL] [Abstract][Full Text] [Related]
6. 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
Schwartz EL; Baptiste N; Megati S; Wadler S; Otter BA
Cancer Res; 1995 Aug; 55(16):3543-50. PubMed ID: 7627962
[TBL] [Abstract][Full Text] [Related]
7. Formation of conjugates of 2-fluoro-beta-alanine and bile acids during the metabolism of 5-fluorouracil and 5-fluoro-2-deoxyuridine in the isolated perfused rat liver.
Sweeny DJ; Barnes S; Diasio RB
Cancer Res; 1988 Apr; 48(8):2010-4. PubMed ID: 2964897
[TBL] [Abstract][Full Text] [Related]
8. A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil.
Zhang R; Liu T; Soong SJ; Diasio RB
Biochem Pharmacol; 1993 May; 45(10):2063-9. PubMed ID: 8512588
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
Cao S; Rustum YM
Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
[TBL] [Abstract][Full Text] [Related]
10. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Spears CP; Shahinian AH; Moran RG; Heidelberger C; Corbett TH
Cancer Res; 1982 Feb; 42(2):450-6. PubMed ID: 6173112
[TBL] [Abstract][Full Text] [Related]
11. Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.
Van Laar JA; Rustum YM; Van der Wilt CL; Smid K; Kuiper CM; Pinedo HM; Peters GJ
Cancer Chemother Pharmacol; 1996; 39(1-2):79-89. PubMed ID: 8995503
[TBL] [Abstract][Full Text] [Related]
12. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Ciccolini J; Peillard L; Evrard A; Cuq P; Aubert C; Pelegrin A; Formento P; Milano G; Catalin J
Clin Cancer Res; 2000 Apr; 6(4):1529-35. PubMed ID: 10778986
[TBL] [Abstract][Full Text] [Related]
14. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
15. 19F nuclear magnetic resonance analysis of the carbamate reaction of alpha-fluoro-beta-alanine (FBAL), the major catabolite of fluoropyrimidines. Application to FBAL carbamate determination in body fluids of patients treated with 5'-deoxy-5-fluorouridine.
Martino R; Malet-Martino MC; Vialaneix C; Lopez A; Bon M
Drug Metab Dispos; 1987; 15(6):897-904. PubMed ID: 2893719
[TBL] [Abstract][Full Text] [Related]
16. Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: assessment with metabolic (19)F MR imaging.
Brix G; Bellemann ME; Haberkorn U
Magn Reson Med; 1999 Nov; 42(5):936-43. PubMed ID: 10542353
[TBL] [Abstract][Full Text] [Related]
17. A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
Spector T; Cao S
Clin Colorectal Cancer; 2010 Jan; 9(1):52-4. PubMed ID: 20100689
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Nishikawa Y; Funakoshi T; Horimatsu T; Miyamoto S; Matsubara T; Yanagita M; Nakagawa S; Yonezawa A; Matsubara K; Muto M
Cancer Chemother Pharmacol; 2017 Mar; 79(3):629-633. PubMed ID: 28204913
[TBL] [Abstract][Full Text] [Related]
19. Direct 19F NMR spectroscopic observation of 5-fluorouracil metabolism in the isolated perfused mouse liver model.
Cabanac S; Malet-Martino MC; Bon M; Martino R; Nedelec JF; Dimicoli JL
NMR Biomed; 1988 Jun; 1(3):113-20. PubMed ID: 3152774
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Naguib FN; Hao SN; el Kouni MH
Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
